CA3027857C - Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells - Google Patents

Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells Download PDF

Info

Publication number
CA3027857C
CA3027857C CA3027857A CA3027857A CA3027857C CA 3027857 C CA3027857 C CA 3027857C CA 3027857 A CA3027857 A CA 3027857A CA 3027857 A CA3027857 A CA 3027857A CA 3027857 C CA3027857 C CA 3027857C
Authority
CA
Canada
Prior art keywords
vector
expression
cells
cell
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3027857A
Other languages
English (en)
French (fr)
Other versions
CA3027857A1 (en
Inventor
Paola Grandi
Ndukaku Mgbechinyere AMANKULOR
Joseph C. Glorioso Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CA3027857A1 publication Critical patent/CA3027857A1/en
Application granted granted Critical
Publication of CA3027857C publication Critical patent/CA3027857C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3027857A 2016-06-14 2017-06-14 Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells Active CA3027857C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350095P 2016-06-14 2016-06-14
US62/350,095 2016-06-14
PCT/US2017/037531 WO2017218689A1 (en) 2016-06-14 2017-06-14 Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Publications (2)

Publication Number Publication Date
CA3027857A1 CA3027857A1 (en) 2017-12-21
CA3027857C true CA3027857C (en) 2023-07-25

Family

ID=60664263

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027857A Active CA3027857C (en) 2016-06-14 2017-06-14 Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Country Status (9)

Country Link
US (1) US11427625B2 (enExample)
EP (1) EP3468588A4 (enExample)
JP (1) JP7184337B2 (enExample)
CN (1) CN109475613B (enExample)
AU (1) AU2017285213B2 (enExample)
CA (1) CA3027857C (enExample)
MX (1) MX2018015542A (enExample)
NZ (1) NZ749586A (enExample)
WO (1) WO2017218689A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
SG11202101581RA (en) * 2017-08-09 2021-03-30 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
US12036256B2 (en) * 2018-04-13 2024-07-16 Regeneron Pharmaceuticals, Inc. Adoptive cellular therapy
EP3874041A1 (en) * 2018-11-01 2021-09-08 Onconetics Pharmaceuticals, Inc. Multi-component vector systems, methods of making, and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2022255538B2 (en) * 2021-04-08 2026-01-22 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes
CN118389408B (zh) * 2024-06-26 2024-11-29 淇嘉科技(苏州)有限公司 炎症性肠病及纤维化体外精准模拟方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031241A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
JP2005523681A (ja) 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
US20150165065A1 (en) 2009-12-31 2015-06-18 Avidbiotics Corp. Non-natural mic proteins
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor

Also Published As

Publication number Publication date
EP3468588A1 (en) 2019-04-17
CN109475613A (zh) 2019-03-15
EP3468588A4 (en) 2019-12-11
CN109475613B (zh) 2024-02-20
WO2017218689A1 (en) 2017-12-21
US11427625B2 (en) 2022-08-30
JP7184337B2 (ja) 2022-12-06
NZ749586A (en) 2023-06-30
AU2017285213A1 (en) 2019-01-17
JP2019517815A (ja) 2019-06-27
AU2017285213B2 (en) 2024-05-16
US20200148742A1 (en) 2020-05-14
CA3027857A1 (en) 2017-12-21
MX2018015542A (es) 2019-10-14
WO2017218689A9 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
US11427625B2 (en) Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
US11883448B2 (en) Oncolytic HSV vector
RU2536931C2 (ru) Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его
Grandi et al. Design and application of oncolytic HSV vectors for glioblastoma therapy
Chiocca et al. Viral therapy for glioblastoma
Mohyeldin et al. Gene and viral therapy for glioblastoma: a review of clinical trials and future directions
JP2002335965A (ja) 細胞特異的発現複製ベクター
CN1871034B (zh) 用新型腺病毒治疗癌症的方法和组合物
WO2020106566A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
US20070225245A1 (en) Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof
Burton et al. Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors
JP2024508088A (ja) 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス
CA2471822C (en) Cell-specific herpes simplex virus expression/replication vector comprising icp4 and human calponin gene promoter
CN109337928A (zh) 通过过表达腺相关病毒受体提高基因治疗效率的方法
US20120134964A1 (en) Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus
ES2358188T3 (es) Vector de expresión/replicación específico para células.
TW202102677A (zh) 經修飾腺病毒及含有其之醫藥
HK1236992B (en) Oncolytic hsv vector
Branch TARGETING CANCER THERAPIES

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220614

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804